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Purpose: Although inconsistent, reports have shown fibrinogen levels to be associ-
ated with atherosclerosis. Accordingly, since cigarette smoking is associated with 
increased levels of fibrinogen and atherosclerosis, it may also affect the association 
between fibrinogen and atherosclerosis. We investigated the associations between 
fibrinogen and carotid intima-media thickness (IMT) according to smoking status 
in a Korean male population. Materials and Methods: Plasma fibrinogen levels 
were measured in 277 men aged 40‒87 years without a history of myocardial in-
farction or stroke. High-resolution B-mode ultrasonography was used to examine 
the common carotid arteries. IMT level was analyzed both as a continuous (IMT-
max, maximum value; IMT-tpm, 3-point mean value) and categorical variable 
(higher IMT; presence of plaque). Serial linear and logistic regression models were 
employed to examine the association between fibrinogen and IMT according to 
smoking status. Results: Fibrinogen levels were positively associated with IMT-
max (standardized β=0.25, p=0.021) and IMT-tpm (standardized β=0.21, p=0.038), 
even after adjusting for age, body mass index, systolic blood pressure, fasting glu-
cose, and total cholesterol to high-density lipoprotein cholesterol ratio in current 
smokers (n=75). No significant association between fibrinogen and IMT, however, 
was noted in former smokers (n=80) or nonsmokers (n=122). Adjusted odds ratios 
(95% confidence interval) for having plaque per one standard deviation higher fi-
brinogen level were 2.06 (1.09‒3.89) for current smokers, 0.68 (0.43‒1.10) for for-
mer smokers, and 1.06 (0.60‒1.87) for nonsmokers. Conclusion: Our findings sug-
gest that cigarette smoking may modify the association between fibrinogen and 
carotid atherosclerosis. Further studies are required to confirm this finding in differ-
ent populations.
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INTRODUCTION
As a hemostatic marker, plasma levels of fibrinogen are associated with the inci-
dence of and mortality from cardiovascular disease.1,2 Fibrinogen levels have also 
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ing. Former smokers comprised those who had smoked 
greater than 100 cigarettes in their lifetime but did not smoke 
recently. Nonsmokers included those who had smoked fewer 
than 100 cigarettes in their lifetime. The height and weight of 
each participant were measured and body mass index was cal-
culated as weight divided by height squared (kg/m2). Partic-
ipants were seated for at least five minutes before blood pres-
sure measurement, and two measurements at least 5-minute 
intervals were obtained by an automatic sphygmomanometer 
(Dinamap 1846 SX/P; GE Healthcare, Waukesha, WI, USA). 
If the two measurements differed by ≥10 mm Hg, for either 
systolic or diastolic blood pressure, an extra measurement was 
taken after 5 minutes; the last two measurements were aver-
aged for analysis. Venous blood samples were collected after 
a minimum 8-hour fast. Enzymatic methods (ADVIA 1800; 
Siemens, New York, USA) were used to measure glucose, al-
anine transaminase, aspartate transaminase, total cholester-
ol, high-density lipoprotein (HDL) cholesterol, and triglycer-
ide levels. Friedewald, et al.’s20 formula was used to calculate 
the level of low-density lipoprotein cholesterol. Turbidimet-
ric immunoassay (ADVIA 1800; Siemens, New York, USA) 
was used to measure high-sensitivity C-reactive protein. White 
blood cell counts were measured by the impedance method 
with an automatic analyzer (ADIVA120; Siemens, New York, 
USA). Fibrin d-dimer was measured via an enzyme linked 
fluorescent assay (Mini vidas; BioMerieux SA, Lyon, France). 
Plasma fibrinogen level was measured by turbidimetric immu-
noassay (Sta-R; Diagnostica Stago, Asnieres, France). Intra- 
and inter-assay coefficients for fibrinogen were less than 5%.
Carotid artery evaluation
Right and left common carotid arteries were assessed with 
high-resolution B-mode ultrasonography (SSAD-3500SV; 
Aloka, Tokyo, Japan) and a 7.5 MHz linear array transduc-
er. Each participant was placed in the supine position with 
the head turned at a 45° angle contralateral to the scanning 
side. Carotid IMT was measured at the end-diastolic phase 
along the vertical distance between the leading edge of the 
first and second echogenic lines of the far wall of the com-
mon carotid artery (IntimaScope; MediaCross, Tokyo, Ja-
pan). IMT was measured at three points (IMT-tpm) along the 
roughly 20-mm region: both ends and the midpoint of the re-
gion. The maximal IMT value was defined as the greatest 
IMT value along the region. For statistical analysis, IMT-tpm 
was defined as the average value of the right and left sides 
of the common carotid artery; IMT-max comprised the high-
est value for both sides; and higher IMT was operationally 
been shown to be associated with carotid intima-media thick-
ness (IMT),3-6 which is a marker of early atherosclerosis and 
a predictor of atherosclerotic cardiovascular disease.7 Some 
studies, however, have not found a significant association be-
tween fibrinogen level and carotid IMT.8-10 Cigarette smok-
ing, an established risk factor for atherosclerosis, is also linked 
to increased fibrinogen levels.11-13 Possible mechanisms for 
the association between smoking and atherosclerosis include 
endothelial dysfunction, vessel wall injury, oxidative stress, 
platelet activation, and inflammation.14,15 Most of these mech-
anisms are also related to the association between fibrinogen 
level and atherosclerotic cardiovascular disease.16 In this 
context, some studies have proposed that smoking may in-
fluence the association between fibrinogen and cardiovascu-
lar risk.17-19 Therefore, to determine whether smoking status 
may explain the inconsistent relationship between fibrino-
gen levels and atherosclerosis reported in the literature, we 
aimed to assess the association between plasma fibrinogen 
level and carotid IMT according to smoking status in a mid-
dle-aged Korean population.
MATERIALS AND METHODS
Study participants
This study was designed as a cross-sectional analysis of a 
subsample cohort within an ongoing community-based co-
hort study. Between July and August 2010, a fibrinogen an-
cillary study was performed for 796 permanent residents 
(311 men, 485 women) of Ganghwa Island, Incheon, Korea. 
Because only a small number of female participants (2.08%) 
were current smokers, the analysis was limited to male par-
ticipants. Among the 311 men with available fibrinogen lev-
els, 34 individuals were excluded because no carotid IMT 
measurement was available (n=6) or there was a history of 
myocardial infarction or stroke (n=28). A total of 277 men 
were eligible for this study. Informed consent was obtained 
from each participant, and the study protocol was approved 
by the Institutional Review Board of Severance Hospital at 
Yonsei University College of Medicine.
Data collection
A standardized questionnaire administered by trained inter-
viewers was used to collect data on the participants’ age, sex, 
medical history, and smoking status. Current smokers were 
defined as those who had smoked more than 100 cigarettes in 
their lifetime and reported that they were presently smok-
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was used as a marker of dyslipidemia, because it reflects the 
balance between atherogenic and antiatherogenic lipopro-
teins and is known to be associated with the risk of athero-
sclerotic cardiovascular disease.23 Moreover, the ratio ex-
plained IMT variation more than the other markers of 
dyslipidemia in our current analysis, as well as in our previ-
ous reports.24,25 All statistical tests were performed with 
SAS version 9.2 (SAS Inc., Cary, NC, USA). All analyses 
were two-sided and p-values less than 0.05 were regarded 
as statistically significant.
RESULTS
The mean age of study participants (n=277) was 60.4 years, 
and the mean fibrinogen level was 2.9 g/L. Compared with 
current smokers and nonsmokers, former smokers were older 
and had higher fibrinogen levels (Table 1). However, there 
was no significant difference in blood pressure, cholesterol, 
defined as the upper 25% of IMT-tpm measurements. Carot-
id artery plaque was defined as an IMT-max>1.0 mm or an 
area of focal wall thickening that was 100% or greater than 
the IMT of neighboring sites.21,22
Statistical analysis 
Clinical characteristics were compared according to smoking 
status. Differences were assessed with analysis of variance, 
the Kruskal-Wallis test, or the chi-square test. Fisher’s exact 
test was applied if there were less than five observations per 
cell. Linear regression analysis was performed to assess the 
relationship between fibrinogen and continuous IMT values. 
Logistic regression analysis was performed to estimate the 
odds ratio for atherosclerosis (higher IMT or presence of ca-
rotid plaque) per one standard deviation (SD) increase in fi-
brinogen level. All regression analyses were performed be-
fore and after adjusting for age, body mass index, systolic 
blood pressure, fasting glucose, and ratio of total cholesterol 
to HDL cholesterol. The ratio of total to HDL cholesterol 
Table 1. Characteristics of the Participants According to Smoking Status
Characteristics Nonsmokers (n=80) Former smokers (n=122) Current smokers (n=75) p value
Mean±SD
Age, yr 59.5±10.4 63.4±9.7 56.6±9.0 <0.001
Body mass index, kg/m2 24.6±3.0 24.8±3.0 23.6±3.1 0.016
Systolic BP, mm Hg 117.9±16.2 119.7±14.6 118.4±18.3 0.704
Diastolic BP, mm Hg 73.1±9.6 73.8±9.5 75.6±10.8 0.276
Total cholesterol, mg/dL 189.2±24.6 189.3±33.5 185.5±34.4 0.673
HDL cholesterol, mg/dL 41.0±7.9 40.7±8.7 41.8±11.6 0.715
LDL cholesterol, mg/dL 118.9±24.0 118.2±28.6 109.5±33.3 0.076
Aspartate transaminase, IU/L 24.0±6.5 25.1±7.4 33.3±40.0 0.012
Alanine transaminase, IU/L 24.1±10.1 24.1±10.3 29.0±32.1 0.159
Leukocyte count, K/uL 5.3±1.3 5.9±1.6 6.4±1.6 <0.001
Fibrinogen, g/L 2.72±0.5 2.94±0.7 2.88±0.6 0.044
IMT-tpm, mm 0.72±0.14 0.76±0.18 0.72±0.17 0.084
IMT-max, mm 0.97±0.30 1.04±0.46 0.98±0.32 0.360
Median [inter-quartile range]
Triglycerides, mg/dL 125.5 [98.5‒183] 137.5 [100‒181] 146 [99‒213] 0.560*
Fasting glucose, mg/dL 92.5 [86‒106] 92 [88‒103] 92 [85‒99] 0.356*
C-reactive protein, mg/L 0.68 [0.38‒1.32] 0.88 [0.50‒1.74] 0.81 [0.58‒1.69] 0.067*
Fibrin D-dimer, μg/mL 0.27 [0.20‒0.42] 0.31 [0.24‒0.54] 0.30 [0.21‒0.51] 0.227*
Number (%)
Hypertension 24 (30.0) 41 (33.6) 14 (18.7) 0.074†
Diabetes mellitus 8 (10.0) 13 (10.7) 4 (5.3) 0.421†
Dyslipidemia 0 (0.0) 6 (4.9) 2 (2.7) 0.111‡
Carotid plaque 40 (50.0) 72 (59.0) 37 (49.3) 0.301†
SD, standard deviation; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IMT, intima-media thickness; IMT-tpm, mean value 
of IMT at three points; IMT-max, maximum IMT value.
*Kruskal-Wallis test.
†Chi-square test.
‡Fisher’s exact test.
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Similarly to the findings for IMT-tpm, fibrinogen levels 
showed a positive association with IMT-max in current smok-
ers (p=0.012), but not in former smokers or nonsmokers.
Table 2 shows the relationship between fibrinogen level 
and continuous measures of IMT, before and after adjusting 
for age, body mass index, blood pressure, fasting glucose, 
and total to HDL cholesterol ratio. In nonsmokers and for-
mer smokers, fibrinogen level was not linearly associated 
with IMT-tpm or IMT-max. This null finding was consistent 
before and adjustment for potential confounders. However, 
in current smokers, fibrinogen level was positively associated 
with IMT-tpm (p=0.029) and IMT-max (p=0.012). Even af-
ter adjustment for potential confounders, fibrinogen level 
fasting glucose, or C-reactive protein levels according to smok-
ing status. Former smokers had higher IMT-tpm levels than 
nonsmokers and current smokers, although the difference was 
of borderline statistical significance (p=0.084). There were no 
significant differences in IMT-max or the presence of carotid 
plaque between nonsmokers, former smokers, and current 
smokers.
Fig. 1 displays the relationship between fibrinogen level 
and IMT-tpm according to smoking status. In contrast with 
nonsmokers and former smokers, as fibrinogen levels in-
creased, a significant increase in IMT-tpm was noted in current 
smokers (p=0.029). Fig. 2 depicts the relationship between fi-
brinogen levels and IMT-max according to the smoking status. 
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Fig. 2. Relationship between fibrinogen and IMT-max according to smoking status. (A) Nonsmokers. IMT-max=0.9395+0.0115×fibrinogen, p=0.8594. (B) 
Former smokers. IMT-max=0.9893+0.0183×fibrinogen, p=0.7532. (C) Current smokers. IMT-max=0.5245+0.1596×fibrinogen, p=0.0119. IMT, intima-media thick-
ness; IMT-max, maximum IMT value.
Table 2. Association between Fibrinogen Level and Continuous Measure of IMT According to Smoking Status
Smoking status
IMT-tpm IMT-max
Standardized β R2 p value Standardized β R2 p value
Unadjusted
Nonsmokers (n=80) 0.017 0.0003 0.880 0.020 0.0004 0.859
Former smokers (n=122) 0.084 0.007 0.359 0.029 0.001 0.753
Current smokers (n=75) 0.252 0.064 0.029 0.289 0.084 0.012
Adjusted*
Nonsmokers (n=80) -0.043 0.208 0.692 -0.006 0.196 0.955
Former smokers (n=122) -0.044 0.285 0.605 -0.074 0.168 0.421
Current smokers (n=75) 0.207 0.394 0.038 0.245 0.325 0.021
IMT, intima-media thickness; IMT-tpm, mean value of IMT at three points; IMT-max, maximum IMT value.
*Adjusted for age, body mass index, blood pressure, fasting glucose, total cholesterol/high-density lipoprotein cholesterol ratio.
IM
T-
tp
m
 m
ea
n
IM
T-
tp
m
 m
ea
n
IM
T-
tp
m
 m
ea
n
Fib Fib Fib
1.4 1.8 1.6
1.3 1.6
1.1
1.2
1.2
1.2
1.4
1.4
1.0 1.0
0.8 0.8 0.8
0.9 1.0
0.6 0.6 0.6
0.7
0.5 0.4 0.4
1.50 1.5 1.752.02.00 2.5 2.003.0 2.252.50 3.5 2.504.0 2.753.00 4.5 3.003.25 5.0 3.253.50 5.5 3.503.75 6.0 3.754.00 6.5 4.004.25 4.25 4.50 4.75
A B C
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rosis can be explained in several ways: first, oxidative stress 
from cigarette smoking can modulate the function of fibrin-
ogen and fibrin architecture. Previous studies have suggest-
ed that smoking can contribute to increasing clot strength 
related to the kinetics of clot formation and the rapidity of fi-
brin build up. After exposure to cigarette smoke, fibrin clots 
exhibit thinner fibrin fibers, increased fibrin fiber density, 
and more uniform fiber distribution, compared with pre-
smoking and non-smoking samples.28 These alterations in fi-
brin architecture may contribute to premature coronary ath-
erothrombosis.29 A fibrin clot with a high fiber density would 
cause delayed clot lysis and thrombotic disease.30 Second, 
smoking can affect fibrinolysis via alteration of plasmino-
gen activator inhibitor type 1 (PAI-1).31 Smokers have high-
er levels of PAI-1 than nonsmokers.32 PAI-1 inhibits the fibri-
nolytic pathway by binding both urinary-type plasminogen 
activator and tissue plasminogen activator, which are activa-
tors of plasminogen for fibrin clot lysis. It has been suggest-
ed that high plasma PAI-1 level in smokers can contribute 
to the formation of thrombi.33 In this context, alteration of 
PAI-1 levels due to smoking may be related to carotid ath-
erosclerosis. Finally, serum fibrinogen levels might be an in-
dicator of chronic exposure to cigarette smoke and/or indi-
vidual susceptibility to cigarette smoke. Studies have shown 
that cigarette smoking can increase the fibrinogen levels and 
arterial wall thickness.11,12,34
Interestingly, in the present study, although fibrinogen lev-
els were significantly higher in former smokers than in cur-
rent or nonsmokers, there was no significant association be-
tween fibrinogen and IMT among former smokers. The 
higher fibrinogen concentrations of former smokers were 
largely explained by age distribution. It is known that ageing 
is positively associated with fibrinogen level and other pro-
was significantly associated with both IMT-tpm (p=0.038) 
and IMT-max (p=0.021). In current smokers, fibrinogen 
level explained the variations in IMT-tpm and IMT-max by 
approximately 6% and 8%, respectively.
Table 3 lists the odds ratios for carotid atherosclerosis (de-
fined as higher IMT or presence of carotid plaque) for one 
SD increase in fibrinogen level for nonsmokers, former 
smokers, and current smokers. Fibrinogen level was signifi-
cantly associated with the presence of carotid atherosclerosis 
only in current smokers. This result was consistent before 
and after adjustment for potential confounders. 
DISCUSSION
In this community-based study, the association between fi-
brinogen level and atherosclerosis differed according to 
smoking status. Among current smokers, there was a signifi-
cant positive association between fibrinogen level and carotid 
IMT, even after adjusting for potential confounders. This as-
sociation was not present for nonsmokers or former smokers. 
Some studies have suggested a positive association between 
fibrinogen and atherosclerosis.3-5 However, this positive asso-
ciation has been inconsistently demonstrated.8-10 Our results 
suggest that cigarette smoking might be an effect modifier on 
the association between fibrinogen and atherosclerosis. This 
effect modification by cigarette smoking may at least partial-
ly explain the inconsistent reports of an association between 
fibrinogen and atherosclerosis.
Studies have proposed that an association between fibrin-
ogen and atherosclerotic cardiovascular disease might be af-
fected, at least in part, by smoking.26,27 The effect of smoking 
on the relationship between fibrinogen level and atheroscle-
Table 3. Association between Fibrinogen Level and Categorical Measure of IMT According to Smoking Status
Smoking status
Higher IMT, upper quartile Presence of plaque 
No. of 
cases
Odds ratio (95% CI) for one  
SD increase in fibrinogen 
No. of 
cases
Odds ratio (95% CI) for one  
SD increase in fibrinogen
Unadjusted
Nonsmokers (n=80) 13 1.07 (0.59 to 1.93) 40 1.24 (0.79 to 1.93)
Former smokers (n=122) 38 1.18 (0.81 to 1.72) 72 0.995 (0.69 to 1.43)
Current smokers (n=75) 19 2.01 (1.14 to 3.55) 37 2.00 (1.17 to 3.40)
Adjusted*
Nonsmokers (n=80) 13 0.86 (0.42 to 1.79) 40 1.06 (0.60 to 1.87)
Former smokers (n=122) 38 0.93 (0.58 to 1.50) 72 0.68 (0.43 to 1.10)
Current smokers (n=75) 19 3.59 (1.41 to 9.12) 37 2.06 (1.09 to 3.89)
IMT, intima-media thickness; CI, confidence interval.
*Adjusted for age, body mass index, blood pressure, fasting glucose, total cholesterol/high-density lipoprotein cholesterol ratio.
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ing may modify the association between fibrinogen and ca-
rotid atherosclerosis. The study findings were consistent for 
continuous and categorical measures of atherosclerosis, and 
after adjustment for the potential confounding effects of 
age, obesity, blood pressure, fasting glucose, and cholester-
ol. Further studies of different populations are required to 
confirm the noted interactions between cigarette smoking, 
fibrinogen level, and atherosclerosis.
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